Porcine Fibrin (Guangzhou Baitejing Pharmaceutical Technology)

Adult Attention deficit/hyperactivity disorder (ADHD) is typically treated with pharmacotherapy, but issues like adverse effects and treatment discontinuation remain challenging. While dialectical behavioral therapy (DBT) has shown promise in treating adult ADHD, there is limited literature that synthesizes new data, evaluates overall efficacy, and explores DBT adaptations. This study aims to assess DBT's effectiveness in reducing ADHD symptoms, alleviating comorbid conditions like anxiety and depression, and improving quality of life in adults.

A comprehensive search of PsycINFO, PubMed, Embase, and ScienceDirect was conducted up to June 30, 2024. Randomized controlled trials (RCTs) comparing DBT (with at least two training modules) to standard treatments, placebo, or no treatment/waitlist controls were included. Standardized mean differences (SMDs) were pooled using random-effects models. Publication bias was assessed via funnel plots, the trim-and-fill method, and Egger's tests. Risk of bias and evidence certainty were evaluated using RoB 2 and GRADEPro.

Of 366 identified articles, 8 RCTs met inclusion criteria, totaling 850 participants, with follow-up data for 533. Meta-analysis showed DBT moderately reduced ADHD symptoms (SMD = -0.51 [-0.76, -0.25]) and improved quality of life (SMD = 0.41 [0.15, 0.66]) compared to controls.

These findings suggest DBT's potential as a clinical treatment for adult ADHD, offering an alternative to medication and addressing functional challenges. New DBT adaptations may enhance care accessibility and treatment adherence.

Glioblastoma (GBM) is a highly malignant and aggressive brain tumor with patients typically experiencing a median survival of 15-18 months after diagnosis. Gap junction protein Connexin43 (Cx43) plays a crucial role in GBM by having both tumor-suppressing and tumor-promoting roles. Here, we identify a critical tumor-promoting role of Cx43 in GBM by functioning as a non-canonical phenotypic stability factor and driving partial EMT, which enhances the acquisition of stemness properties in the cells. Using high-grade mouse astrocytoma cell lines, we found that CT2A cells had higher Cx43 gap junction assembly as compared to KR158 cells. The increased Cx43 assembly in CT2A cells activates the NF-κB signaling pathway, promoting a hybrid E/M phenotype and thereby enhancing self-renewal properties. CT2A cells also exhibited collective cell migration, a characteristic feature of hybrid E/M phenotype, stress resistance, and proliferative properties. To verify Cx43's role in NF-κB pathway activation, DBT and DBT-Erp-29 cells (with higher Cx43 expression) were studied, showing increased NF-κB activation in DBT-Erp-29 cells. Interestingly, KR158 cells formed longer tunneling nanotubes to expedite alternative cellular communication due to reduced gap junctional intercellular communication (GJIC). These results offer valuable insights into targeting Cx43-mediated signaling pathways due to the potential tumor-promoting role of Cx43.